Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Leukemia × carfilzomib × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 67 Recurrence 11 Neoplasms, Plasma Cell 6 Neoplasms 2 Waldenstrom Macroglobulinemia 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Plasmacytoma 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, B-Cell, Marginal Zone 1 Lung Neoplasms 1 Leukemia 1 Hodgkin Disease 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 39 venetoclax 28 Cytarabine 25 fludarabine 19 Azacitidine 17 fludarabine phosphate 16 Whole-Body Irradiation 13 Rituximab 12 Mycophenolic Acid 11 Etoposide 11 ruxolitinib 10 Dexamethasone 10 Vincristine 9 Methotrexate 9 Melphalan 9 Decitabine 9 Mercaptopurine 8 Filgrastim 8 Busulfan 8 blinatumomab 7 Tacrolimus 7 Prednisone 7 Granulocyte Colony-Stimulating Factor 7 Daunorubicin 7 pegaspargase 6 ibrutinib 6 Peripheral Blood Stem Cell Transplantation 6 Doxorubicin 6 Dasatinib 6 revumenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02512926 2025-10-15

POE14-01

Stanford University

Phase 1 Completed

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡